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A b s t r a c t
Background: Left ventricular aneurysm (LVA) relates to worse prognosis in patients with myocardial infarction despite successful 
reperfusion treatment. There is no evidence that early detectable biomarkers can predict the risk for the future development of LVA.
Aim: The aim of our study was to investigate the possible predictive value of periprocedural haematological parameters for LVA.
Methods: A total of 281 patients with acute anterior ST-segment elevation myocardial infarction (STEMI) who underwent 
primary percutaneous coronary intervention (pPCI) were enrolled. Haematological parameters were measured on admission 
before pPCI and between 8 and 12 h after pPCI, separately. The development of LVA was evaluated at one-year follow-up. 
The patients were then divided into two groups: an LVA group and a non-LVA group. Univariate and multivariate logistic 
regression analyses were performed to find the predictors of LVA.
Results: A total of 34 (12.1%) patients developed LVA at one-year follow-up after pPCI. Multivariate analyses revealed that 
a 10 × 109/L increase in platelet count 12 h after pPCI (odds ratio [OR] 1.092, 95% confidence interval [CI] 1.015–1.188, 
p = 0.039), peak cardiac troponin I (OR 1.107, 95% CI 1.003–1.215, p = 0.000), and left ventricular ejection fraction (OR 
0.853, 95% CI 0.772–0.943, p = 0.002) were independent risk factors for LVA. For the prediction of LVA, platelet count 12 h 
after pPCI at a cut-off value > 197 × 109/L yielded a receiver operating characteristic-area under the curve (ROC-AUC) of 
0.635 (82.3% sensitivity, 44.1% specificity).
Conclusions: Platelet count after pPCI was significantly associated with the development of LVA in anterior STEMI patients 
and may be available for early risk stratification of future LVA formation.
Key words: platelet count, left ventricular aneurysm, primary percutaneous coronary intervention, ST-segment elevation 
myocardial infarction
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INTRODUCTION
Left ventricular aneurysm (LVA) is a common complication of 
acute myocardial infarction (MI) and occurs in 10% to 38% of 
patients [1–3]. The occurrence of LVA is mostly due to a large 
MI area, resulting in damage or even loss of local myocardial 
contractility [4]. This pathophysiological process eventually 
leads to ventricular remodelling. Most of LVAs occur at the 
apex of the ventricle or in a few locations near the bottom of 
the posterior wall. Formation of LVA may damage ventricular 
geometry, leading to the limitation of systole and diastole abil-
ity [5], and may worsen the prognosis of MI, for instance by 
inducing angina [6], malignant arrhythmia [7], embolism [8], or 
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even cardiac rupture [9] and death. LVA formation is divided 
into two periods: a period of extension of MI area (5–10 days 
after onset of MI) and a period of ventricular remodelling 
(2–4 weeks after MI). The necrotic myocardium is gradually 
replaced by fibrous tissue and the ventricular wall becomes 
thinner [6]. LVA progressively damages the function of residual 
surviving myocardium, so early diagnosis and appropriate 
treatment of ventricular aneurysm after MI are essential. 
Currently, the diagnostic techniques for LVA are progressing 
rapidly: electrocardiography, echocardiography, ventricular 
angiography, magnetic resonance imaging, radionuclide 
ventriculography, and myocardial perfusion imaging can be 
used for clinical diagnosis of ventricular aneurysm forma-
tion. Clinical risk factors for the development of LVA include 
anterior MI and poor collateral supply through smoking [10]. 
However, there is still no evidence of a reliable biomarker to 
predict the risk of future development of LVA, especially at 
the early phase of MI onset. Various haematological param-
eters can be easily and routinely available before primary 
percutaneous coronary intervention (pPCI) in ST-segment 
elevation myocardial infarction (STEMI) patients. High levels 
of neutrophil count have been proven to be associated with 
an increased risk of clinical adverse events after acute MI [11]. 
Therefore, we hypothesised that there might be some associa-
tion between periprocedural haematological parameters and 
LVA formation. The purpose of our study was to investigate 




The initial study population of this retrospective cohort study 
was composed of 289 consecutive patients diagnosed with 
acute anterior STEMI, undergoing pPCI within 12 h from 
symptom onset, between September 2014 and March 2017, 
at the cardiology department of our hospital. Acute anterior 
STEMI was defined as typical chest pain lasting longer than 
30 min, with new ST-segment elevation at the J point in 
at least two contiguous leads of > 2 mm (0.2 mV) in men 
or > 1.5 mm (0.15 mV) in women in leads V2–V3 and/or 
of > 1 mm (0.1 mV) in other contiguous anterior leads on 
admission electrocardiogram, and an increase in cardiac 
enzyme levels, which was defined as being above the 99th 
percentile cut-off point for cardiac troponin I (cTnI) or creatine 
kinase-MB fraction (CK-MB) [12]. Exclusion criteria included 
cardiogenic shock on admission, receipt of thrombolytic drugs 
in the previous 24 h, active infections, systemic inflammatory 
disease history, clinical evidence of autoimmune disease or 
haematological proliferative disorders, known malignancy, and 
liver disease. Patients with renal failure and patients who were 
lost to follow-up (e.g. death before the index echocardiogra-
phy examination) were also excluded. A total of 281 patients 
were included in the present study. The study protocol was 
approved by the Beijing Shijitan Hospital Ethics Committee 
of Capital Medical University.
Definitions of clinical criteria
Left ventricular aneurysm was defined as outward bulging, 
with akinetic or dyskinetic motion, of the left ventricular wall 
during the entire cardiac cycle. Echocardiography at one-year 
(at 10–14 months from the onset of acute MI) follow-up was 
used for the diagnosis of LVA. Hypertension was defined as 
blood pressure > 140/90 mmHg or treatment for hyperten-
sion before admission. Hyperlipidaemia was defined as total 
cholesterol level > 5.72 mmol/L, low-density lipoprotein 
cholesterol level > 3.64 mmol/L, or treatment for hyper-
lipidaemia. Diabetes mellitus was defined as fasting plasma 
glucose level > 7.0 mmol/L, postprandial blood glucose 
level > 11.1 mmol/L, haemoglobin A1c level > 6.5%, or 
treatment for diabetes mellitus.
Coronary angiography and PCI procedure
Pharmacological treatment of all enrolled patients before pPCI 
included aspirin (300 mg loading dose), clopidogrel (600 mg 
loading dose), and an intravenous bolus of unfractionated 
heparin at a dose of 70 U/kg of body weight. Primary PCI 
was performed using the standard radial or femoral ap-
proach with a 6- or 7-French guiding catheter. The stent was 
deployed in all patients. The use of balloon pre-dilatation or 
post-dilatation, the type of stent (bare metal or drug-eluting), 
and the use of thrombus aspiration was left to the operator’s 
decision. The glycoprotein IIb/IIIa receptor inhibitor tirofiban 
was given at the discretion of the operator and started during 
PCI procedure with 10 μg/kg intracoronary bolus followed by 
0.15 μg/kg/min intravenous infusion. Technically successful 
stent implantation was defined as residual stenosis < 10% in 
the culprit lesion after the procedure, as visually assessed by 
angiography, without occlusion of a significant side branch, 
flow-limiting dissection, distal embolisation, or angiographic 
thrombus. Thrombolysis in Myocardial Infarction (TIMI) flow 
grades were evaluated by the consensus of two experienced 
interventional cardiologists, who were blind to the clinical 
and laboratory data, by using quantitative cardiovascular 
angiographic software. No-reflow after pPCI was defined 
as TIMI flow grade ≤ 2 after vessel recanalisation despite 
the absence of angiographic stenosis, spasm, dissection, or 
thrombosis. Normal reflow was defined as post-intervention 
TIMI grade 3 flow.
Laboratory analysis and echocardiography
In all patients, venous blood samples were drawn into standard 
EDTA-containing tubes on admission in the emergency room 
before pPCI and between 8 and 12 h (8–12 h) after pPCI. The 
haematological parameters such as neutrophil, platelet, and 
lymphocyte count were measured by an automated blood 
cell counter (XS-1000i; Sysmex Co, Kobe, Japan). The levels 
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of creatinine and cardiac enzymes were also measured in all 
patients, with the use of standard methods. To determine the 
peak value of cardiac enzyme level, blood samples for troponin I 
(TnI) and CK-MB were obtained from a peripheral vein, after 
admission to the intensive coronary care unit, every 6 h during 
the first 48 h and every 12 h during the rest of the stay therein. 
Echocardiography investigation was routinely performed at 
8–12 h after pPCI and at one-year (10–14 months from the 
onset of acute MI) follow-up, using a GE ViVidE7 ultrasound 
machine (GE Healthcare, Piscataway, NJ, USA) with a 3.5-MHz 
transducer. Left ventricular ejection fraction (LVEF) was meas-
ured by Simpson’s method in the two-dimensional echocar-
diographic apical four-chamber view.
Statistical analysis
Continuous variables are presented as mean ± standard 
deviation or as median and interquartile range. The differ-
ences between groups were tested by independent samples 
t-test or Mann-Whitney U test. Categorical variables were 
summarised as percentages and compared with the c2 test. 
Multivariate logistic regression analysis, including covariates 
found to have a significant association with LVA in univariate 
analysis, was used to identify independent predictors of LVA. 
The receiver operating characteristic (ROC) curve was used 
to determine the cut-off value of platelet count to predict the 
LVA development. Statistical analysis was performed using the 
SPSS 22.0 Statistical Package Programme for Windows (SPSS 
Inc., Chicago, IL, USA). A two-sided p-value of < 0.05 was 
considered significant.
RESULTS
Our study included 281 patients (229 men; mean age, 
62 ± 13 years) with acute anterior STEMI, who had undergone 
pPCI. Among all the subjects, 82.2% (n = 231) of patients 
had multi-vessel disease and 44.1% (n = 124) of patients had 
a proximal left anterior descending artery (LAD) lesion. Final 
procedural success was obtained in all patients. However, final 
TIMI flow grade ≤ 2 was found in 51 (18.1%) patients. In the 
current study, the incidence of LVA was 12.1% (n = 34) at 
one-year follow-up after pPCI.
Haematological parameters were acquired on admission 
before pPCI and 8–12 h after pPCI, separately. As shown 
in Table 1, neutrophil count, monocyte count, and platelet 
distribution width were significantly higher 8–12 h after pPCI 
than on admission before the procedure. However, lympho-
cyte count and haemoglobin and haematocrit levels detected 
8–12 h after the procedure were significantly lower compared 
with their levels on admission (Table 2).
Study participants were divided into two groups: an 
LVA group and a non-LVA group, according to their echocar-
diographic result at one-year follow-up. Patients’ baseline 
clinical parameters and procedural characteristics for LVA 
and non-LVA groups are shown in Table 2. Patients with LVA 
development at one-year follow-up had higher peak cTnI level 
(99.1 ng/mL vs. 29.6 ng/mL, p = 0.000), more frequent Killip 
class ≥ II (52.9% vs. 16.2%, p = 0.000), lower LVEF on admis-
sion (45.0% vs. 55.0%, p = 0.000), and a higher rate of proxi-
mal LAD lesion (79.4% vs. 50.6%, p = 0.002) than patients 
in the non-LVA group. The comparison of haematological 
parameters between the two groups on admission and 8–12 h 
after pPCI is presented in Table 3. White blood cell count was 
significantly higher in the LVA group than in the non-LVA group 
at both time points. Platelet count and platelet/lymphocyte 
ratio 8–12 h after pPCI were significantly higher in the LVA 
group than in the non-LVA group, but not at the time of 
admission before pPCI. No significant differences between 
the LVA and non-LVA groups at either time point were found 
in neutrophil count, haemoglobin level, lymphocyte count, 
monocyte count, platelet distribution width neutrophil/lym-
phocyte ratio, mean platelet volume-to-lymphocyte ratio, or 
lymphocyte-to-monocyte ratio (Table 3).
The results of the univariate logistic regression analyses 
for risk factors of the development of LVA are summarised in 
Table 4. Killip class ≥ II, peak cTnI, final TIMI flow grade ≤ 2, 
Table 1. Haematological parameters of the study population
Variable On admission before pPCI 8–12 h after pPCI p
White blood cell count [×109/L] 9.76 ± 3.06 10.24 ± 3.09 0.065
Neutrophil count [×109/L] 7.17 ± 4.14 8.5 ± 4.62 0.008
Haemoglobin [g/L] 144.16 ± 20.72 138.86 ± 18.84 0.002
Platelet count [×109/L] 214.67 ± 58.58 211.02 ± 57.26 0.464
Haematocrit [%] 42.30 ± 4.84 40.86 ± 4.61 0.000
Mean platelet volume [fL] 10.33 ± 0.90 10.47 ± 1.11 0.129
Lymphocyte count [×109/L] 2.29 ± 1.15 1.67 ± 1.19 0.000
Monocyte count [×109/L] 0.54 ± 0.26 0.61 ± 0.31 0.040
Platelet distribution width [%] 12.38 ± 1.91 12.81 ± 2.16 0.017
Data are presented as mean ± standard deviation. pPCI — primary percutaneous coronary intervention
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proximal LAD lesion, reduced LVEF, white blood cell count, 
platelet/lymphocyte ratio, and every 10 × 109/L increase 
in platelet count 8–12 h after pPCI were significantly associ-
ated with LVA. These variables were subsequently entered 
as independent variables in multivariate logistic regression 
analysis. In multivariate analyses, peak cTnI (odds ratio [OR] 
1.107, 95% confidence interval [CI] 1.003–1.215, p = 0.000), 
LVEF (OR 0.853, 95% CI 0.772–0.943, p = 0.002), and 
every 10 × 109/L increase in platelet count 8–12 h after 
pPCI (OR 1.092, 95% CI 1.015–1.188, p = 0.039) were 
independent risk factors for LVA at one-year follow-up 
(Table 5). The most discriminative cut-off values of platelet 
count to predict LVA were 197 × 109/L, with a sensitiv-
ity of 82.3% and a specificity of 44.1% (area under curve 
0.635, 95% CI 0.576–0.692; p = 0.004; as shown in 
Figures 1 and 2).
Table 2. Baseline clinical and procedural characteristics of the study population divided according to left ventricular aneurysm 
(LVA) formation
Characteristics Non-LVA (n = 247) LVA (n = 34) p
Age [years] 61.7 ± 13.7 64.8 ± 13.0 0.220
Male sex 202 (81.8%) 24 (70.6%) 0.164
Diabetes mellitus 71 (28.7%) 15 (44.1%) 0.074
Hypertension 149 (60.3%) 22 (64.7%) 0.709
Hyperlipidaemia 155 (62.8%) 23 (67.6%) 0.705
Active smokers 111 (44.9%) 13 (38.2%) 0.581
Killip class ≥ II 40 (16.2%) 18 (52.9%) 0.000
Peak cTnI [ng/mL] 29.6 (10.5–92.2) 99.1 (43.9–217.7) 0.000
Medication at hospital discharge:
b-blockers 152 (61.5%) 24 (70.6%) 0.349
ACEIs or ARBs 137 (55.5%) 19 (55.8%) 0.963
Aldosterone receptor blockers 17 (6.9%) 11 (32.4%) 0.000
Statin 234 (94.7%) 30 (88.2%) 0.135
Thiazide or loop diuretic 44 (17.8%) 13 (38.2%) 0.011
Echocardiographic variables:
Initial LVEDD [mm] 49.0 (45.0–52.0) 50.0 (48.0–56.0) 0.016
LVEDD one year later [mm] 50.0 (46.0–54.0) 60.5 (57.0–65.0) 0.000
Initial LVEF [%] 55.0 (50.0–60.0) 45.0 (40.8–49.0) 0.000
LVEF one year later [%] 57.0 (53.0–62.0) 40.0 (37.8–47.0) 0.000
Time from symptom onset to pPCI: 0.323
< 3 h 63 (25.5%) 10 (29.4%)
3–6 h 98 (39.6%) 9 (26.5%)
6–12 h 86 (34.9%) 15 (44.1%)
Multi-vessel disease 204 (82.6%) 27 (79.4%) 0.253
Proximal LAD lesion 125 (50.6%) 27 (79.4%) 0.002
Stent length [mm] 30.0 (21.0–48.0) 30.5 (18.0–39.0) 0.117
Stent diameter [mm] 3.00 (2.75–3.50) 2.93 (2.50–3.19) 0.069
Stent max pressure [atm] 16.0 (12.0–8.0) 14.0 (10.0–16.0) 0.287
IABP support 15 (6.1%) 4 (11.8%) 0.263
Use of thrombus aspiration 67 (27.1%) 10 (29.4%) 0.838
Tirofiban use 151 (61.1%) 18 (52.9%) 0.358
Final TIMI flow grade ≤ 2 42 (17.0%) 9 (26.5%) 0.232
*Data are presented as mean ± standard deviation, number (percentage), or median (interquartile range). ACEIs — angiotensin-converting 
enzyme inhibitors; ARBs — angiotensin receptor blockers; cTnI — cardiac troponin I; IABP — intra-aortic balloon pump; LAD — left anterior 
descending; LVEDD — left ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction; pPCI — primary percutaneous coronary 
intervention; TIMI — Thrombolysis In Myocardial Infarction 
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DISCUSSION
The mortality rate in patients with LVA is up to six times higher 
than in patients without LVA [13]. In the present study, there 
were 34 (12.1%) acute anterior STEMI patients who developed 
LVA at one-year follow-up after pPCI. Multivariate analysis 
revealed that peak cTnI, LVEF, and platelet count 8–12 h 
after pPCI were significantly associated with the development 
of LVA. The formation of LVA was due to myocardial tissue 
necrosis, wall thinning, and loss of contractility of infarct 
area during healing processes, resulting in the akinesia (no 
movement) or dyskinesia (paradoxical ballooning) during 
ventricular systole. Various types of serious complications can 
occur because of LVA, particularly heart failure, ventricular 
arrhythmia, and thromboembolism. Early risk stratification 
to detect patients at high risk of developing LVA after pPCI 
is very important for the prevention and treatment of this 
condition. With the improvement of reperfusion strategies, 
such as PCI, the incidence of LVA has significantly decreased 
in recent years [14]. Mori et al. [15] found that in the pPCI 
era peak CK and final TIMI flow grade were significantly 
associated with the development of LVA in acute anterior 
STEMI patients undergoing pPCI. The association between 
elevated peak cardiac enzyme (cTnI) and LVA development 
was demonstrated in our study. Higher peak troponin level 
was revealed to be associated with larger infarct size. Shen et 
al. [13] found that LVA often results from a large infarct and 
subsequent severe global left ventricular dysfunction. The 
same pathophysiological relationship might also explain the 
significant association between initial LVEF and LVA devel-
opment in our study. However, we did not identify the final 
TIMI flow grade ≤ 2 as an independent risk factor for LVA in 
one-year follow-up after acute anterior STEMI in the present 
Table 3. Haematological parameters in left ventricular aneurysm (LVA) and non-LVA groups
Variable No LVA (n = 247) LVA (n = 34) p
Haematological parameters on admission:
White blood cell count [×109/L] 9.6 ± 2.9 10.7 ± 3.8 0.046
Neutrophil count [×109/L] 7.0 ± 3.3 8.2 ± 3.8 0.223
Haemoglobin [g/L] 144.6 ± 21.4 140.5 ± 13.8 0.316
Platelet count [×109/L] 212.3 ± 47.4 233.6 ± 65.3 0.065
Haematocrit [%] 42.4 ± 4.9 41.3 ± 3.5 0.719
Mean platelet volume [fL] 10.3 ± 0.9 10.3 ± 1.0 0.681
Lymphocyte count [×109/L] 2.26 ± 0.34 2.49 ± 0.44 0.500
Monocyte count [×109/L] 0.54 ± 0.17 0.59 ± 0.21 0.301
Platelet distribution width [%] 12.4 ± 1.9 12.3 ± 2.1 0.719
Neutrophil/lymphocyte ratio 4.56 ± 2.69 5.65 ± 2.21 0.329
Platelet/lymphocyte ratio 124.6 ± 46.2 144.2 ± 48.3 0.189
Mean platelet volume-to-lymphocyte ratio 6.30 ± 3.09 6.86 ± 3.28 0.489
Lymphocyte-to-monocyte ratio 4.37 ± 1.80 5.64 ± 1.70 0.085
Haematological parameters 12 h after pPCI:
White blood cell count [×109/L] 10.1 ± 2.9 11.5 ± 3.9 0.013
Neutrophil count [×109/L] 8.38 ± 3.92 9.39 ± 3.60 0.405
Haemoglobin [g/dL] 138.7 ± 20.9 136.1 ± 17.9 0.491
Platelet count [×109/L] 207.0 ± 58.1 233.7 ± 56.8 0.012
Haematocrit [%] 40.98 ± 4.6 39.81 ± 4.5 0.702
Mean platelet volume [fL] 10.49 ± 1.16 10.30 ± 1.04 0.365
Lymphocyte count [×109/L] 1.70 ± 0.54 1.49 ± 0.56 0.399
Monocyte count [×109/L] 0.60 ± 0.21 0.65 ± 0.24 0.513
Platelet distribution width [%] 12.8 ± 2.1 12.7 ± 2.4 0.943
Neutrophil/lymphocyte ratio 6.60 ± 2.65 8.20 ± 2.46 0.122
Platelet/lymphocyte ratio 157.4 ± 59.1 195.8 ± 57.9 0.012
Mean platelet volume-to-lymphocyte ratio 8.22 ± 3.79 9.10 ± 4.45 0.325
Lymphocyte-to-monocyte ratio 2.98 ± 1.14 2.75 ± 1.17 0.195 
Data are presented as mean ± standard deviation. Abbreviations — see Tables 1 and 2
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Table 4. Univariate logistic regression analysis to investigate the determinants of left ventricular aneurysm
Independent variables OR 95% CI p
Age 0.984 0.958–1.010 0.220
Male sex 0.963 0.455–2.310 0.730
Hypertension 0.824 0.390–1.741 0.612
Diabetes mellitus 0.504 0.242–1.047 0.066
Hyperlipidaemia 0.801 0.373–1.718 0.568
Active smokers 1.307 0.626–2.727 0.476
Killip class ≥ II 5.822 2.740–12.371 0.000
Time from symptom onset to pPCI (3-h increase) 0.915 0.576–1.452 0.706
Peak cardiac troponin I 1.008 1.005–1.012 0.000
Multi-vessel disease (vs. single-vessel disease) 0.729 0.324–1.638 0.444
Proximal LAD lesion (vs. distal LAD lesion) 3.765 1.580–8.967 0.003
Tirofiban use 0.715 0.348–1.470 0.362
Final TIMI flow grade ≤ 2 2.475 1.118–5.477 0.025
Left ventricular ejection fraction (initial) 0.869 0.826–0.915 0.000
White blood cell count on admission 1.109 1.000–1.230 0.051
White blood cell count 12 h after pPCI 1.134 1.024–1.256 0.016
Neutrophil count on admission 1.029 0.978–1.082 0.272
Neutrophil count 12 h after pPCI 1.017 0.976–1.059 0.423
Lymphocyte count on admission 1.062 0.889–1.268 0.507
Lymphocyte count 12 h after pPCI 0.659 0.369–1.175 0.157
Monocyte count on admission 1.943 0.550–6.869 0.303
Monocyte count 12 h after pPCI 1.262 0.623–2.554 0.519
Haemoglobin on admission 0.992 0.976–1.008 0.319
Haemoglobin 12 h after pPCI 0.994 0.979–1.010 0.491
Haematocrit on admission 0.013 0.101–12.713 0.252
Haematocrit 12 h after pPCI 0.105 0.100–9.962 0.165
Platelet count on admission 1.001 0.957–1.047 0.964
Platelet count 12 h after pPCI 1.079 1.016–1.147 0.014
Mean platelet volume on admission 0.912 0.591–1.409 0.679
Mean platelet volume 12 h after pPCI 0.880 0.667–1.162 0.368
Platelet distribution width on admission 0.963 0.783–1.184 0.718
Platelet distribution width 12 h after pPCI 0.994 0.841–1.175 0.943
Neutrophil/lymphocyte ratio on admission 1.025 0.973–1.078 0.352
Neutrophil/lymphocyte ratio 12 h after pPCI 1.039 0.988–1.093 0.138
Platelet/lymphocyte ratio on admission 1.003 0.998–1.008 0.191
Platelet/lymphocyte ratio 12 h after pPCI 1.005 1.001–1.008 0.017
Mean platelet volume-to-lymphocyte ratio on admission 1.031 0.946–1.124 0.489
Mean platelet volume-to-lymphocyte ratio 12 h after pPCI 1.033 0.968–1.103 0.326
Lymphocyte-to-monocyte ratio on admission 1.055 0.979–1.137 0.161
Lymphocyte-to-monocyte ratio (12 h after pPCI) 0.828 0.622–1.103 0.196
CI — confidence interval; OR — odds ratio; other abbreviations — see Tables 1 and 2
study, which is not consistent with an earlier study conducted 
by Mori et al. [14]. Different sample demographics and pPCI 
procedural characteristics may explain some of the differences 
between the two studies. 
Various haematological parameters can be easily and rou-
tinely available before or after pPCI in STEMI patients. While 
there are several reports describing the predictive values of 
the haematological parameters for the prognosis of patients 
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Table 5. Multivariate logistic regression analysis to investigate the determinants of left ventricular aneurysm
Independent variables OR 95% CI p
Killip class ≥ II 1.856 0.433–7.957 0.405
Peak cardiac troponin I 1.107 1.003–1.215 0.000
Proximal LAD lesion 2.466 0.875–6.946 0.088
Final TIMI flow grade ≤ 2 1.986 0.694–5.683 0.201
Left ventricular ejection fraction 0.853 0.772–0.943 0.002
White blood cell count 12 h after pPCI 0.997 0.881–1.129 0.962
Platelet count 12 h after pPCI 1.092 1.015–1.188 0.039
Platelet/lymphocyte ratio 12 h after pPCI 1.001 0.996–1.006 0.613 
Abbreviations — see Tables 1, 2 and 4
Figure 2. Dot plot distribution of platelet count 8–12 h after 
primary percutaneous coronary intervention (pPCI) for subjects 
with or without left ventricular aneurysm (LVA).
Figure 1. Receiver operating characteristic curve of platelet  
count 8–12 h after primary percutaneous coronary interven-
tion for the prediction of left ventricular aneurysm formation
with acute MI undergoing pPCI, there are no reports show-
ing the association between the haematological parameters 
and LVA development. The main purpose of the present 
study was to test the hypothesis that there may be some as-
sociations between periprocedural haematological parameters 
and future LVA formation. Although some of the complete 
blood count parameters, such as high neutrophil count [11], 
low lymphocyte count [16], mean platelet volume [17], 
neutrophil-to-lymphocyte ratio [18], platelet-to-lymphocyte 
ratio [19], and mean platelet volume-to-lymphocyte ratio 
[20], have been previously associated with poor cardiovascu-
lar outcomes after acute MI, we did not find any significant 
association between these parameters, acquired before or 
after pPCI, and LVA formation at one year follow-up after 
the procedure. After MI, inflammatory cells such as neu-
trophils and monocytes infiltrate the infarcted myocardium 
and secrete a variety of inflammatory cytokines. This healing 
process may weaken the myocardium and lead to infarct ex-
pansion under the ventricular stress, and finally to ventricular 
aneurysm formation [21]. In our study the white blood cell 
count was significantly higher in the LVA group than in the 
non-LVA group. Neutrophil counts on admission and 8–12 h 
after pPCI tended to be higher (although not significantly) in 
the LVA group than in the non-LVA group. 
Mueller et al. [22] found that platelet count remained 
a significant independent predictor of mortality in patients 
with unstable angina and non-STEMI patients during 
long-term follow-up in a multivariate Cox regression analysis 
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adjusted for baseline demographic, clinical, and angiographic 
variables. Nikolsky et al. [23] found that high baseline platelet 
count in patients with acute MI is a powerful independent 
predictor of death and re-infarction within the first year after 
pPCI. The present study revealed that platelet count 8–12 h 
after pPCI was an independent risk factor for future LVA 
formation. Previous studies have found that platelets not 
only promote thrombus formation in the pathophysiological 
process of MI but may also trigger inadequate inflamma-
tory response and subsequent ventricular remodelling [24]. 
Despite their participation in the circulatory inflammation 
response, activated platelets also bind to the wall of inflamed 
microvessels by attaching either directly to endothelial cells 
or to leucocytes that are already adherent to the vessel wall. 
Platelets can release markers of inflammation and directly 
activate other inflammatory cells, which can lead to the 
further release of inflammatory cytokines and amplify the 
inflammatory response in the microvessels [25]. The cross 
talk between platelets, leucocytes, and endothelial cells may 
impair the microvascular function in the infarct zone even 
in patients with successful mechanical reperfusion therapy. 
Yamamuro et al. [26] reported that even if successful reperfu-
sion is achieved in epicardial coronary arteries, microvascular 
dysfunction, measured by coronary flow velocity, causes insuf-
ficient reperfusion of the infarcted myocardium, leading to 
left ventricular dysfunction and LVA formation.
The limitations of the present study lie in its single-centre, 
retrospective and observational design, and a small study 
population. Selection bias may be also considered a limitation 
because three patients who died before one-year follow-up 
were excluded from the final analysis. Inflammatory mark-
ers, such as C-reactive protein, were not routinely measured 
before or after pPCI; their measurement may have helped to 
elucidate the association between platelet count, inflamma-
tion response, and LVA development. Also, we did not collect 
detailed information about total periprocedural dosing of un-
fractionated heparin used in the study population, which may 
have influenced the post-procedural platelet counts. Further 
large prospective population-based studies, with a detailed 
examination of the signalling pathway and downstream targets 
of platelet activation, are needed to confirm the association 
between the platelet count and LVA in patients with STEMI 
receiving pPCI.
In conclusion, platelet count after pPCI was significantly 
associated with the development of LVA in anterior STEMI 
patients. Platelet count may be available for early risk stratifica-
tion of future LVA formation in acute STEMI patients and might 
allow the optimisation of preventative therapy to improve the 
outcomes of patients with STEMI.
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